Q-omics provides the consensus-scored CTF1 profile across patient tissues and cancer cell-line models. CTF1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CTF1 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, CTF1 RNA expression shows 15,634 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KICH, and TGCT as cancer lineages where CTF1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CTF1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CTF1 survival associations across molecular data types. CTF1 RNA expression shows survival associations in the most cancer types (21), followed by mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CTF1 RNA expression–survival associations across cancer types. High CTF1 expression shows unfavorable associations in LGG, but favorable associations in UVM, LUAD, MESO, ACC and HNSC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CTF1 RNA expression.
This table summarizes CTF1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KICH for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CTF1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CTF1 shows lower tumor expression in KICH, KIRC, LUAD, LUSC, UCEC and BLCA. The KICH box plot shows higher CTF1 RNA expression in normal versus tumor tissue (log2 FC = −2.050, t-test p < 0.001).
This table shows molecular features associated with CTF1 in patient tissues and cancer cell lines. In patient samples, CTF1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CTF1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and UPPER_AERODIGESTIVE_TRACT.
